Nitto-denko Corporation

Quark Pharmaceuticals, Inc.

Raptor Pharmaceuticals Inc.

Horizon Orphan LLC

Elizabeth C Squiers

Elena Feinstein

Shai Erlich

Igor Mett

Yoshiro Niitsu

Lei Yu

Hagar Kalinski

Yasunobu Tanaka

Sharon Avkin-Nachum

Hirokazu Takahashi

Xiaomei Jin

Ning Chen

Thomas E Daley

Daniel J Odenheimer

Daniel Rothenstein

Nir Sharon

Kin-Hung Peony Yu

Sharon Avkin-nachum

Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.

Modulation of HSP47 expression

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.

Methods and compositions for preventing ischemia reperfusion injury in organs

Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity.

4-methylpyrazole formulations for inhibiting ethanol intolerance

Growing community of inventors

Half Moon Bay, CA, United States of America

Elizabeth C Squiers